Takeover activity has been on the rise in biotech as the cost of bringing a new drug to market has soared. Eden Rahim, Manager of the Next Edge Bio-Tech Plus Fund, says M&A is an important aspect of biotech investing. here are 15 companies in his fund that he says are potential takeover targets. The top 3 candidates: Acadia, Intercept and Portola.